Yet, studies using genetically engineered mouse (GEM) models indicate that Kdm6a suppresses PDA progression through a demethylase-independent mechanism, raising the possibility that other KDM members may mediate hypoxia-driven reprogramming of the malignant state 26. The gene discussed is KDM6A; the disease is Patent ductus arteriosus.